Gastric Inhibitory Polypeptide Receptor – Drugs In Development, 2021

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Gastric Inhibitory Polypeptide Receptor – Drugs In Development, 2021, outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) – Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 8, 8, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System, Musculoskeletal Disorders, Cardiovascular and Respiratory which include indications Obesity, Type 2 Diabetes, Diabetes, Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Non Alcoholic Fatty Liver Disease (NAFLD), Parkinson's Disease, Cardiovascular Risk Factors, Circadian Rhythm Sleep Disorders, Diastolic Heart Failure, Fibrosis, Idiopathic Pulmonary Fibrosis, Osteoporosis, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Type 1 Diabetes (Juvenile Diabetes) and Unspecified Metabolic Disorders.

Furthermore, this report also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)

– The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects

– The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc

Antag Therapeutics ApS

Bainan Biotech ApS

Carmot Therapeutics Inc

D&D Pharmatech Co Ltd

Eli Lilly and Co

Great Bay Bio Holdings Ltd

Hanmi Pharmaceuticals Co Ltd

Kariya Pharmaceuticals IVS

Longevity Biotech Inc

Novo Nordisk AS

Zealand Pharma AS

Zhejiang Doer Biologics Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Overview

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development

Amgen Inc

Antag Therapeutics ApS

Bainan Biotech ApS

Carmot Therapeutics Inc

D&D Pharmatech Co Ltd

Eli Lilly and Co

Great Bay Bio Holdings Ltd

Hanmi Pharmaceuticals Co Ltd

Kariya Pharmaceuticals IVS

Longevity Biotech Inc

Novo Nordisk AS

Zealand Pharma AS

Zhejiang Doer Biologics Corp

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles

(semaglutide + GIP analogue) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AMG-133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic to Agonize GLP-1R, GIPR and GLR for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-868 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DAJC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DD-03 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DR-10624 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DR-10625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DR-10627 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Agonize GIP and GLP-2 for Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBT-6030 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3437943 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3493269 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3537021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Antagonize GIPR for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptide to Activate GIPR for Type I Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GIPR and GLP1R for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide 1 for Type 2 Diabetes, Obesity and Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide 1 to Agonize GIPR and GLP1R for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease and Type 1 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize GIPR and GLP1R for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize GIP, GR and GLP-1R for Gastrointestinal and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirzepatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-6590 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Products

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Product Development Milestones

Featured News & Press Releases

Jun 29, 2021: Latest data from SURPASS trials demonstrate Tirzepatide provided meaningful blood sugar reductions and weight loss

Jun 26, 2021: Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes

Jun 25, 2021: Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

Jun 11, 2021: Lilly announces webcast to provide diabetes portfolio update at ADA

May 21, 2021: Lilly’s tirzepatide meets endpoints in type 2 diabetes trial

May 04, 2021: Carmot Therapeutics announces investigational new drug (IND) clearance for CT-868, a dual GLP-1 and GIP receptor modulator for the treatment of overweight and obese patients with type 2 diabetes

Mar 05, 2021: Lilly’s tirzepatide leads to body weight reductions in type 2 diabetes trial

Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program

Feb 17, 2021: Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program

Dec 14, 2020: Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes

Dec 10, 2020: Lilly reports positive data from trial of tirzepatide for type 2 diabetes

Nov 11, 2020: Lilly announces webcast to provide an overview of Tirzepatide Phase 3 clinical program

Jul 22, 2020: FDA grants fast track designation for Hanmi LAPSTriple agonist

Jun 10, 2020: Lilly begins dosing in cardiovascular outcomes trial of tirzepatide

Mar 11, 2020: Hanmi's NASH treatment wins more orphan drug status

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Amgen Inc, 2021

Pipeline by Antag Therapeutics ApS, 2021

Pipeline by Bainan Biotech ApS, 2021

Pipeline by Carmot Therapeutics Inc, 2021

Pipeline by D&D Pharmatech Co Ltd, 2021

Pipeline by Eli Lilly and Co, 2021

Pipeline by Great Bay Bio Holdings Ltd, 2021

Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021

Pipeline by Kariya Pharmaceuticals IVS, 2021

Pipeline by Longevity Biotech Inc, 2021

Pipeline by Novo Nordisk AS, 2021

Pipeline by Zealand Pharma AS, 2021

Pipeline by Zhejiang Doer Biologics Corp, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports